<h2 data-section-id="1m27jkc" data-start="0" data-end="52"><strong>Chemotherapy-Induced Peripheral Neuropathy Market</strong></h2>
<p data-start="54" data-end="700">The <a href="https://www.delveinsight.com/report-store/cipn-market"><strong>Chemotherapy-Induced Peripheral Neuropathy (CIPN) market</strong></a> is expected to witness substantial growth across the 7MM due to increasing chemotherapy utilization and the absence of approved preventive therapies. In 2025, the market size was estimated at nearly USD 1 billion, with the US accounting for approximately 54% of the total market share. The market is projected to grow at a CAGR of 14.2% during 2026&ndash;2036, driven by rising demand for effective neuropathy management and emerging targeted therapies. Novel agents focusing on nerve protection and pain modulation are expected to transform the treatment landscape over the forecast period.</p>
<h3 data-start="702" data-end="725"><strong data-start="702" data-end="725">Key Market Insights</strong></h3>
<ul data-start="726" data-end="1033">
<li data-section-id="fxrdyn" data-start="726" data-end="772">2025 market size in the 7MM: USD 1 billion</li>
<li data-section-id="1bvm8ms" data-start="773" data-end="809">Expected CAGR (2026&ndash;2036): 14.2%</li>
<li data-section-id="h8vc4q" data-start="810" data-end="861">US contributed nearly 54% of total market share</li>
<li data-section-id="uj831u" data-start="862" data-end="951">QUTENZA is projected to generate the highest revenue among emerging therapies by 2036</li>
<li data-section-id="14akpjk" data-start="952" data-end="1033">Rising cancer incidence and chemotherapy exposure remain major growth drivers</li>
</ul>
<h2 data-section-id="1qnga03" data-start="1040" data-end="1098"><strong>Chemotherapy-Induced Peripheral Neuropathy Epidemiology</strong></h2>
<p data-start="1100" data-end="1757"><a href="https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-epidemiology-forecast"><strong>Chemotherapy-Induced Peripheral Neuropathy</strong></a> remains one of the most common complications associated with anticancer therapies, particularly platinum compounds, taxanes, and vinca alkaloids. In 2025, total incident cases across the 7MM were estimated at nearly 1.6 million. The US represented 41% of total cases, followed by EU4 and the UK with 41%, while Japan accounted for 18%. Long-term disease burden remains significant, as approximately 40&ndash;47% of cancer survivors continued experiencing CIPN symptoms nearly six years after treatment. Oxaliplatin-induced peripheral neuropathy is especially prevalent, affecting nearly 70% of treated patients globally.</p>
<h3 data-start="1759" data-end="1786"><strong data-start="1759" data-end="1786">Epidemiology Highlights</strong></h3>
<ul data-start="1787" data-end="2038">
<li data-section-id="1q23er1" data-start="1787" data-end="1835">Total incident cases in the 7MM: 1.6 million</li>
<li data-section-id="5ozbuh" data-start="1836" data-end="1853">US share: 41%</li>
<li data-section-id="19b5l1z" data-start="1854" data-end="1883">EU4 and the UK share: 41%</li>
<li data-section-id="11hvnhj" data-start="1884" data-end="1904">Japan share: 18%</li>
<li data-section-id="b6hfuw" data-start="1905" data-end="1973">40&ndash;47% survivors reported persistent CIPN symptoms after 6 years</li>
<li data-section-id="690yd6" data-start="1974" data-end="2038">Around 70% patients developed oxaliplatin-induced neuropathy</li>
</ul>
<h2 data-section-id="1yqfvey" data-start="2045" data-end="2099"><strong>Chemotherapy-Induced Peripheral Neuropathy Pipeline</strong></h2>
<p data-start="2101" data-end="2878">The <a href="https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight"><strong>Chemotherapy-Induced Peripheral Neuropathy pipeline</strong></a> is evolving steadily with several companies developing therapies targeting neuropathic pain, nerve regeneration, and prevention strategies. Current treatment approaches, including SNRIs, opioids, and tricyclic antidepressants, provide only modest symptom relief, creating strong demand for innovative therapeutics. Emerging therapies such as Halneuron, ATX01, and ART-123 are designed to address underlying nerve dysfunction through novel mechanisms of action. Additionally, Recomodulin (ART-123) is anticipated to become the first approved preventive therapy for CIPN in Japan. Increasing research investments and multimodal therapeutic strategies are expected to strengthen the future treatment landscape significantly.</p>
<h3 data-start="2880" data-end="2902"><strong data-start="2880" data-end="2902">Key Emerging Drugs</strong></h3>
<ul data-start="2903" data-end="3015">
<li data-section-id="2yuoyz" data-start="2903" data-end="2939"><a href="https://www.delveinsight.com/report-store/halneuron-emerging-drug-insight-and-market-forecast"><strong>Halneuron</strong></a> &ndash; Dogwood Therapeutics</li>
<li data-section-id="w9auzi" data-start="2940" data-end="2958">ATX01 &ndash; AlgoTx</li>
<li data-section-id="bapld4" data-start="2959" data-end="3015">ART-123 &ndash; Asahi Kasei Pharma/Veloxis Pharmaceuticals</li>
</ul>
<h3 data-start="3017" data-end="3036"><strong data-start="3017" data-end="3036">Pipeline Trends</strong></h3>
<ul data-start="3037" data-end="3246" data-is-last-node="" data-is-only-node="">
<li data-section-id="1n8mriz" data-start="3037" data-end="3079">Focus on preventive therapies for CIPN</li>
<li data-section-id="iuc6f5" data-start="3080" data-end="3134">Increasing development of topical and SC therapies</li>
<li data-section-id="1ix80r3" data-start="3135" data-end="3188">Novel sodium channel modulators gaining attention</li>
<li data-section-id="1ut0aut" data-start="3189" data-end="3246" data-is-last-node="">Strong unmet need due to lack of FDA-approved therapies</li>
</ul>

Chemotherapy Induced Peripheral Neuropathy Market

Chemotherapy Induced Peripheral Neuropathy (CIPN) Market

Chemotherapy-Induced Peripheral Neuropathy Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape